Hovedbudskap
- Neuraminidasehemmere erstatter ikke vaksinering av risikopasienter.
- Perioden med influensasymptomer kan reduseres med 1 – 2,5 dager, men også behandlede pasienter vil gjennomgående være syke noen dager.
− Det er sett få bivirkninger i studier, men rapporter om bronkokonstriksjon etter markedsføring har gjort at forsiktighetsreglene er skjerpet.
- 1.
Mäkela MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene OK et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000; 40: 42 – 8.
- 2.
Jefferson T, Demicheli V, Deeks J, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. The Cochrane Library 2000;
- 3.
Oxford: Update Software, 2000. 3. The MIST study group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877 – 81.
- 4.
Murphy KR, Eivindson A, Pauksens K, Stein WJ, Tellier G, Watts R et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest 2000; 20: 337 – 49.
- 5.
Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337: 874 – 80.
- 6.
Nicholson KG, Aoki FY, Osterhaus ADME, Trottier S, Carewicz O, Mercier CH et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized, controlled trial. Lancet 2000; 355: 1845 – 50.
- 7.
Nguyen-Van-Tam JS. Zanamivir for influenza: a public health perspective. BMJ 1999; 319: 655 – 6.
- 8.
Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336 – 43.
- 9.
Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crips A. Zanamivir in the prevention of influenza among healthy adults: a randomized, controlled trial. JAMA 1999; 282: 31 – 5.
- 10.
Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, Hammond JM et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 1282 – 9.
- 11.
Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343: 1778 – 87.
- 12.
Läkemedelsverket, Sverige. (www.mpa.se/mono/relenza.html).
- 13.
Ramsay S. UK guidelines for influenza drug updated. Lancet 2000; 356: 1830.
- 14.
DTB and UK doctors reject Relenza. Scrip 2001; nr. 2601: 4.